Litigation Details for Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-06-17 |
| Court | District Court, D. Delaware | Date Terminated | 2023-09-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc. |
| Jury Demand | None | Referred To | Jennifer L. Hall |
| Parties | TEVA PHARMACEUTICALS DEVELOPMENT, INC. | ||
| Patents | 10,034,873; 10,039,757; 9,724,342 | ||
| Attorneys | Katherine P. Kieckhafer | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-06-17 | 1 | Complaint | of U.S. Patent Nos. 9,724,342, 10,039,757, and 10,034,873 (collectively, the “Asserted Patents”). … The ’757 Patent will expire on July 18, 2031. 29. U.S. Patent No. 10,034,873 (the “’873… COUNT III: INFRINGEMENT OF US PATENT NO. 10,034,873 58. Exelixis incorporates …FOR PATENT INFRINGEMENT 1. This is an action for patent infringement under the patent laws…the ’342 Patent, at least claim 1 of the ’757 Patent, and at least claim 1 of the ’873 Patent. The Asserted | External link to document |
| 2021-08-27 | 13 | Answer to Complaint | U.S. Patent Nos. 9,724,342 (the “’342 Patent”); 10,039, 757 (the “’757 Patent”); and 10,034,873 (the…U.S. Patent Nos. 9,724,342 (the “’342 Patent”), 10,039,757 (the “’757 Patent”), and 10,034,873 (the…DEFENSE: INVALIDITY OF US PATENT NO. 10,034,873 Each claim of the ’873 Patent is invalid for failing…Certification Concerning U.S. Patent Nos. 9,724,342, 10,039,757 and 10,034,873” (the “First Notice Letter…Certification Concerning U.S. Patent Nos. 9,724,342, 10,039,757 and 10,034,873” (the “Second Notice Letter | External link to document |
| 2021-06-17 | 3 | ANDA Form | 10,039,757 and Patent No. 10,034,873). Thirty Month Stay Deadline: On or about: 11/4/2023. (mal) (Entered: 06/21…of Expiration of Patents: July 9, 2033 (Patent No. 9,724,342) and July 18, 2031 (Patent No. 10,039,757 … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …cv-00228-RGA-JLH 1:22-cv-00945-RGA Cause: 35:271 Patent Infringement 17 June 2021 19 …19 September 2023 1:21-cv-00871 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction | External link to document |
| 2021-06-17 | 4 | Patent/Trademark Report to Commissioner | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,724,342 ;10,039,757 ;10,034,873. (mal) …cv-00228-RGA-JLH 1:22-cv-00945-RGA Cause: 35:271 Patent Infringement 17 June 2021 19 …19 September 2023 1:21-cv-00871 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction…: Federal Question None Nature of Suit: 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction | External link to document |
| 2023-09-19 | 52 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,724,342; 10,039,757; 10,034,873. (Attachments…cv-00228-RGA-JLH 1:22-cv-00945-RGA Cause: 35:271 Patent Infringement 17 June 2021 19 …19 September 2023 1:21-cv-00871 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction…: Federal Question None Nature of Suit: 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
